A novel mechanism of action for anti-thymocyte globulin:: Induction of CD4+CD25+Foxp3+ regulatory T cells

被引:311
作者
Lopez, Marta
Clarkson, Michael R.
Albin, Monica
Sayegh, Mohamed H.
Najafian, Nader
机构
[1] Brigham & Womens Hosp, Transplantat Res Ctr, EBRC, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 10期
关键词
D O I
10.1681/ASN.2006050422
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
T cell-depleting agents are being tested as part of clinical tolerance strategies in humans with autoimmunity and transplantation. The immunosuppressive activity of anti-thyrnocyte globulin (ATG) has been thought to result primarily from depletion of peripheral lymphocytes. Herein is reported for the first time that ATG but not anti-CD52 mAb (alemtuzumab) or the IL-21Z antagonists causes rapid and sustained expansion of CD4(+)CD25(+) T cells when cultured with human peripheral blood lymphocytes. These cells display enhanced expression of the regulatory markers glucocorticoid-induced TNF receptor, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and forkhead box P3 and efficiently suppress a direct alloimmune response of the original responder lymphocytes. It is interesting that the cells do not suppress memory responses to the recall antigen mumps. Ex vivo expansion of regulatory T cells is due mainly to conversion of CD4(+)CD25(+) into CD4(+)CD25(+) T cells and to a lesser degree to proliferation of natural CD4(+)CD25(+) T cells. The induction of regulatory T cells depends on production of Th2 cytokines in the generating cultures. These novel data suggest that ATG not only may promote expansion/ generation of regulatory T cells but also may be useful in future ex vivo expansion of these cells for cellular therapy in autoirnmunity and clinical transplantation.
引用
收藏
页码:2844 / 2853
页数:10
相关论文
共 31 条
[1]   Homeostasis of peripheral CD4+ T cells:: IL-2Rα and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers [J].
Almeida, ARM ;
Legrand, N ;
Papiernik, M ;
Freitas, AA .
JOURNAL OF IMMUNOLOGY, 2002, 169 (09) :4850-4860
[2]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[3]   Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[4]  
Beiras-Fernandez A, 2003, Exp Clin Transplant, V1, P79
[5]   Regulatory T-cell therapy: is it ready for the clinic? [J].
Bluestone, JA .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :343-349
[6]   Faith supported by reason: Mechanistic support for the use of polyclonal antibodies in transplantation. [J].
Brennan, DC .
TRANSPLANTATION, 2003, 75 (05) :577-578
[7]   Apoptosis and transplantation tolerance [J].
Chiffoleau, E ;
Walsh, PT ;
Turka, L .
IMMUNOLOGICAL REVIEWS, 2003, 193 (01) :124-145
[8]   Development and function of CD25+CD4+ regulatory T cells [J].
Fehérvari, Z ;
Sakaguchi, S .
CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (02) :203-208
[9]   Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells (Reprinted from vol 4, pg 330-336, 2003) [J].
Fontenot, Jason D. ;
Gavin, Marc A. ;
Rudensky, Alexander Y. .
JOURNAL OF IMMUNOLOGY, 2017, 198 (03) :986-992
[10]   Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins [J].
Genestier, L ;
Fournel, S ;
Flacher, M ;
Assossou, O ;
Revillard, JP ;
Bonnefoy-Berard, N .
BLOOD, 1998, 91 (07) :2360-2368